KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Resmed (RMD) Other Working Capital Changes (2016 - 2025)

Historic Other Working Capital Changes for Resmed (RMD) over the last 17 years, with Q4 2025 value amounting to $106.4 million.

  • Resmed's Other Working Capital Changes rose 14387.82% to $106.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$22.3 million, marking a year-over-year decrease of 12643.15%. This contributed to the annual value of -$82.6 million for FY2025, which is 17171.85% down from last year.
  • Latest data reveals that Resmed reported Other Working Capital Changes of $106.4 million as of Q4 2025, which was up 14387.82% from -$2.3 million recorded in Q3 2025.
  • Resmed's 5-year Other Working Capital Changes high stood at $106.6 million for Q1 2022, and its period low was -$79.4 million during Q1 2025.
  • In the last 5 years, Resmed's Other Working Capital Changes had a median value of $22.2 million in 2023 and averaged $23.6 million.
  • Its Other Working Capital Changes has fluctuated over the past 5 years, first surged by 85500.4% in 2022, then crashed by 197967.48% in 2025.
  • Resmed's Other Working Capital Changes (Quarter) stood at $7.0 million in 2021, then soared by 326.72% to $29.9 million in 2022, then rose by 9.09% to $32.6 million in 2023, then surged by 33.92% to $43.6 million in 2024, then skyrocketed by 143.88% to $106.4 million in 2025.
  • Its Other Working Capital Changes stands at $106.4 million for Q4 2025, versus -$2.3 million for Q3 2025 and -$47.0 million for Q2 2025.